Ikarian Capital, LLC Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $645,793 - $4.66 Million	-238,300 Reduced 18.35%	1,060,100 $3.01 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $15.6 Million - $23.9 Million	1,296,335 Added 62776.51%	1,298,400 $19.1 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $37,335 - $48,424	2,065 New	2,065 $37,000
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $4.16 Million - $6.14 Million	150,000 New	150,000 $4.4 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $1.73 Million - $3.12 Million	-100,800 Reduced 28.73%	250,000 $7.04 Million
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $690,480 - $2.01 Million	100,800 Added 40.32%	350,800 $6.76 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $3.21 Million - $8.23 Million	250,000 New	250,000 $3.21 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.